Ganirelix
Ganirelix is a GnRH antagonist medication used in fertility treatments to prevent premature ovulation during controlled ovarian stimulation for assisted reproductive technologies (ART). It works by blocking gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland, thereby suppressing the luteinizing hormone (LH) surge that could otherwise trigger early egg release. This medication is primarily used by women undergoing in vitro fertilization (IVF) or similar fertility procedures.
Ganirelix is a fertility medication that prevents premature ovulation during IVF cycles by blocking LH surge.
Key facts at a glance
- ATC
- H01CC01
- RxNorm
- 35825
- Generic
- Ganirelix
- Class
- atc-h01
- Brands
- Fyremadel
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe, solution
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 250mcg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- not applicable
- Maximum
- consult physician
- Frequency
- not applicable
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mcg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks; ganirelix is used in fertility treatment and not indicated for pregnant patients
regular fetal monitoring if exposure occurs
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second trimesteravoid
discontinue if pregnancy occurs during treatment
regular prenatal care
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
third trimesteravoid
not recommended during late pregnancy
standard prenatal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingavoid
not recommended during breastfeeding; discontinue breastfeeding or avoid drug depending on necessity
monitor infant for adverse effects
pediatric_age
pediatric under 18not applicable
not indicated for use in pediatric patients; contraindicated in children and adolescents
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderly 65 plususe with caution; no specific dose adjustment defined
ganirelix is primarily used in women of reproductive age undergoing fertility treatment; limited data in elderly
monitor renal and hepatic function
Use with caution and monitor for adverse effects.
renal_impairment
mild to moderateno specific dose adjustment recommended based on limited data
use with caution; limited pharmacokinetic data available
monitor renal function
Use with caution and monitor for adverse effects.
hepatic_impairment
mild to moderateno specific dose adjustment established
use with caution; limited data on use in hepatic impairment
monitor liver function tests
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
FDA approval for controlled ovarian stimulation in IVF
Drug class
Gonadotropin-releasing hormone antagonist classification
Common uses
Assisted reproductive technology treatment
Route of administration
Method of drug administration
Ganirelix is indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation for assisted reproductive technologies (ART), particularly in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles.
As a GnRH antagonist, Ganirelix competitively binds to GnRH receptors in the anterior pituitary gland, blocking the action of endogenous GnRH. This leads to rapid suppression of LH and FSH secretion, preventing the premature LH surge that could result in egg release before optimal follicular development is achieved.
Ganirelix is administered by subcutaneous injection, typically during the mid-to-late follicular phase of an IVF cycle. Common side effects may include injection site reactions, headache, and abdominal discomfort. It should only be used under the supervision of a fertility specialist as part of a comprehensive ART treatment protocol.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy